BackgroundMinimal knowledge exists regarding the outcome, prognosis and optimal treatment strategy for patients with pulmonary large cell neuroendocrine carcinomas (LCNEC) due to their rarity. We aimed to identify factors affecting survival and recurrence after resection to inform current treatment strategies.MethodsWe retrospectively reviewed 72 patients who had undergone a curative resection for LCNEC in 8 centers between 2000 and 2015. Univariable and multivariable analyses were performed to identify the factors influencing recurrence, disease-specific survival and overall survival. These included age, gender, previous malignancy, ECOG performance status, symptoms at diagnosis, extent of resection, extent of lymphadenectomy, additional chemo- and/or radiotherapy, tumor location, tumor size, pT, pleural invasion, pN and pStage.ResultsMedian follow-up was 47 (95%CI 41-79) months; 5-year disease-specific and overall survival rates were 57.6% (95%CI 41.3-70.9) and 47.4% (95%CI 32.3-61.1). There were 22 systemic recurrences and 12 loco-regional recurrences. Tumor size was an independent prognostic factor for systemic recurrence [HR: 1.20 (95%CI 1.01-1.41); p=0.03] with a threshold value of 3cm (AUC=0.71). For tumors 3cm and >3cm, 5-year freedom from systemic recurrence was 79.2% (95%CI 43.6-93.6) and 38.2% (95%CI 20.6-55.6) (p<0.001) and 5-year disease-specific survival was 60.7% (95%CI 35.1-78.8) and 54.2% (95%CI 32.6-71.6) (p=0.31), respectively.ConclusionsA large proportion of patients with surgically resected LCNEC will develop systemic recurrence after resection. Patients with tumors >3cm have a significantly higher rate of systemic recurrence suggesting that adjuvant chemotherapy should be considered after complete resection of LCNEC >3cm, even in the absence of nodal involvement.

Large Cell Neuroendocrine Tumor Size >3 cm Negatively Impacts Long-Term Outcomes After R0 Resection / Cattoni, M.; Vallieres, E.; Brown, L. M.; Sarkeshik, A. A.; Margaritora, S.; Siciliani, A.; Filosso, P. L.; Guerrera, F.; Imperatori, A.; Rotolo, N.; Farjah, F.; Wandell, G.; Costas, K.; Mann, C.; Hubka, M.; Kaplan, S.; Farivar, A. S.; Aye, R. W.; Louie, B. E.. - In: WORLD JOURNAL OF SURGERY. - ISSN 0364-2313. - 43:7(2019), pp. 1712-1720. [10.1007/s00268-019-04951-x]

Large Cell Neuroendocrine Tumor Size >3 cm Negatively Impacts Long-Term Outcomes After R0 Resection

Filosso P. L.;
2019

Abstract

BackgroundMinimal knowledge exists regarding the outcome, prognosis and optimal treatment strategy for patients with pulmonary large cell neuroendocrine carcinomas (LCNEC) due to their rarity. We aimed to identify factors affecting survival and recurrence after resection to inform current treatment strategies.MethodsWe retrospectively reviewed 72 patients who had undergone a curative resection for LCNEC in 8 centers between 2000 and 2015. Univariable and multivariable analyses were performed to identify the factors influencing recurrence, disease-specific survival and overall survival. These included age, gender, previous malignancy, ECOG performance status, symptoms at diagnosis, extent of resection, extent of lymphadenectomy, additional chemo- and/or radiotherapy, tumor location, tumor size, pT, pleural invasion, pN and pStage.ResultsMedian follow-up was 47 (95%CI 41-79) months; 5-year disease-specific and overall survival rates were 57.6% (95%CI 41.3-70.9) and 47.4% (95%CI 32.3-61.1). There were 22 systemic recurrences and 12 loco-regional recurrences. Tumor size was an independent prognostic factor for systemic recurrence [HR: 1.20 (95%CI 1.01-1.41); p=0.03] with a threshold value of 3cm (AUC=0.71). For tumors 3cm and >3cm, 5-year freedom from systemic recurrence was 79.2% (95%CI 43.6-93.6) and 38.2% (95%CI 20.6-55.6) (p<0.001) and 5-year disease-specific survival was 60.7% (95%CI 35.1-78.8) and 54.2% (95%CI 32.6-71.6) (p=0.31), respectively.ConclusionsA large proportion of patients with surgically resected LCNEC will develop systemic recurrence after resection. Patients with tumors >3cm have a significantly higher rate of systemic recurrence suggesting that adjuvant chemotherapy should be considered after complete resection of LCNEC >3cm, even in the absence of nodal involvement.
2019
43
7
1712
1720
Large Cell Neuroendocrine Tumor Size &gt;3&nbsp;cm Negatively Impacts Long-Term Outcomes After R0 Resection / Cattoni, M.; Vallieres, E.; Brown, L. M.; Sarkeshik, A. A.; Margaritora, S.; Siciliani, A.; Filosso, P. L.; Guerrera, F.; Imperatori, A.; Rotolo, N.; Farjah, F.; Wandell, G.; Costas, K.; Mann, C.; Hubka, M.; Kaplan, S.; Farivar, A. S.; Aye, R. W.; Louie, B. E.. - In: WORLD JOURNAL OF SURGERY. - ISSN 0364-2313. - 43:7(2019), pp. 1712-1720. [10.1007/s00268-019-04951-x]
Cattoni, M.; Vallieres, E.; Brown, L. M.; Sarkeshik, A. A.; Margaritora, S.; Siciliani, A.; Filosso, P. L.; Guerrera, F.; Imperatori, A.; Rotolo, N.; Farjah, F.; Wandell, G.; Costas, K.; Mann, C.; Hubka, M.; Kaplan, S.; Farivar, A. S.; Aye, R. W.; Louie, B. E.
File in questo prodotto:
File Dimensione Formato  
070_Large Cell Neuroendocrine Tumor Size 3 cm Negatively Impacts Long-Term Outcomes After R0 Resection.pdf

Accesso riservato

Dimensione 412.99 kB
Formato Adobe PDF
412.99 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1317823
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 8
social impact